Esma KOBAK TUR

Dr. Esma KOBAK TUR


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2021 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
GKGulay Kenangil
Gulay Kenangil
MDMehmet Demir
Mehmet Demir
ETEsma KOBAK TUR
Esma KOBAK TUR
FDFusun Domac
Fusun Domac

24 September 2023 in Neurological Research
Verified
Journal Article
Closed access
ETEsma KOBAK TUR
Esma KOBAK TUR
BABuse Cagla Ari
Buse Cagla Ari
This research targeted to understand the impact of clinical findings, non-motor symptoms, white matter hyperintensities (WMHs), and metabolic features on cognition in Parkinson's disease patients with mild cognitive impairment (PD-MCI). Sixty-one PD patients sundered into two groups: PD-MCI and normal cognition (PD-NC). We assessed cognition using Montreal Cognitive Assessment-TR (MoCA-TR) and Frontal Assessment Battery (FAB). We used the modified Hoehn&Yahr staging scale (mH&Y), Unified Parkinson's Disease Rating Scale (UPDRS), Freezing of Gait questionnaire, Beck Depression Inventory, Parkinson's disease sleep scale-2, Pittsburgh sleep quality index, Epworth sleepiness scale, and Non-motor symptoms questionnaire to evaluate all patients. We used the Fazekas scale to evaluate the WMHs and also investigated all laboratory parameters affecting cognitive functions. Duration of disease, UPDRS-Motor part, age, disease stage, and daytime sleepiness were dramatically higher in the PD-MCI group than in PD-NC (p < 0.05). WMHs and homocysteine were higher in the PD-MCI group than in the controls (p = 0.016 and p < 0.001, respectively). There was a negative correlation between cognition and duration of disease, age, disease stage, UPDRS-Motor scale, daytime drowsiness, WMHs and homocysteine levels. Homocysteine was negatively related to visuospatial/executive functions (r=-0.303, p = 0.021). WMHs were correlated with global cognition (p =.000 r = .-542), language (p = .001, r = -.434), and delayed recall (p = .011, r = -.332). Mild cognitive impairment is a widespread clinical situation of PD patients and often presents before the motor symptoms. Revealing curable causes that affect cognition before the development of PD-related dementia is crucial in controlling motor findings and reducing the burden of the caretakers.


27 October 2023 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
ETEsma KOBAK TUR
Esma KOBAK TUR
EGEren Gözke
Eren Gözke
Aims: Autonomic dysfunction is a prevalent feature throughout various stages of the disease and can significantly exacerbate the overall impact of the condition. Moreover, it is linked to accelerated disease advances and diminished vitality rates in individuals with Parkinson’s disease (PD). The main goal of this study is to evaluate the prevalence of autonomic symptoms and cognitive findings and investigate their associations with disease-related factors in early-stage PD patients. Methods: A total of 49 individuals diagnosed with PD were enrolled in this study. Disease severity was assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS), and the disease stage was determined through the modified Hoehn & Yahr Rating Scale (mHYRS). By the mH&Y scale, only individuals in the early stages (≤2.5) of the disease were included in this investigation. The evaluation of autonomic symptoms in PD was conducted using the Scales for Outcomes in Parkinson’s Disease for Autonomic Symptoms (SCOPA-AUT) scale. The cognitive functions of the patients were assessed utilizing the Turkish version of the Montreal Cognitive Assessment Scale (MOCA-TR). Results: The study included 44% (n=22) females and 56% (n=27) males as participants. The average age was 61.5±10.1 years. The mean SCOPA-AUT score was 18.9±9.36, with the most prevalent autonomic symptoms related to the gastrointestinal system. A positive correlation was shown with autonomic symptoms and disease stages (p=0.024, r=0.322). However, no significant relationship was found between autonomic symptoms, other disease parameters, and cognition. We observed a notable inverse correlation between the disease stage and cognitive status (p=0.003, r=-0.417). Conclusion: Our study concluded that autonomic dysfunctions manifest from the early stages of Parkinson’s disease and can intensify as the disease progresses. Identifying and addressing these dysfunctions at an early stage would play a pivotal role in lessening the overall impact of the disease.

30 July 2023 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ETEsma KOBAK TUR
Esma KOBAK TUR
BABuse Cagla ARI
Buse Cagla ARI
Aims: Viral infections have been implicated in the development of Parkinson disease (PD). It has been observed that the presence of SARS-CoV-2 in dopaminergic cells can expedite the degeneration process and potentially exacerbate symptoms. The objective of this study was to assess the impact of the COVID-19 pandemic on individuals with PD. Methods: A total of 60 patients were enrolled in the study. The severity of the disease was assessed using the using the Unified Parkinson's Disease Rating Scale (UPDRS), while the stage of the disease was determined using modified Hoehn &Yahr Rating Scale (m HYRS). Various measures were taken to evaluate the patients’ well-being, including the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Parkinson's Disease Quality of Life Questionnaire (PDQ-39), and Impact of Events Scale (IES-R) scores. The researchers also recorded the UPDRS scores, levodopa equivalent doses (LED), and BMI of the patients before and after the lockdown period. Subsequently, the collected data were compared to identify any significant changes. Results: The difference in UPDRS, LED and BMI of the patients before and after the lockdown was statistically significant (p<0.05). Furthermore, there was a significant increase in UPDRS motor score, BAI, and PDQ-39 values among female patients compared to male patients (p<0.05). Comparing patients with and without COVID-19 infection, it was observed that patients who had contracted COVID-19 demonstrated a statistically significant increase in m HYRS and UPDRS motor scores, and PDQ-39 values after the lockdown (p<0.05). To assess the impact of various factors on the quality of life, multiple linear regression analysis was performed. The analysis revealed that COVID-19-positive patients and female patients experienced a more pronounced effect on their quality of life (p<0.05). Moreover, quality of life was found to be affected by disease stage, depression, anxiety, the IES-R scores increase, as well as by deteriorating sleep quality (p<0.05). Conclusion: During the COVID-19 pandemic, PD patients experienced a worsening of clinical symptoms and increased treatment requirements. Furthermore, their quality of life was negatively affected, particularly among females and those who contracted COVID-19 infection. It is crucial to develop supportive treatment strategies targeting neuropsychological symptoms, as these could greatly contribute to the overall management and well-being of PD patients.

30 October 2019 in Neurological Sciences and Neurophysiology
Verified
Journal Article
Open access
ETEsma KOBAK TUR
Esma KOBAK TUR
GKGulay Kenangil
Gulay Kenangil
FDFusun Mayda Domac
Fusun Mayda Domac
Neurological Sciences and Neurophysiology